BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) CAO Erin Burkhart sold 2,286 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $90.00, for a total value of $205,740.00. Following the completion of the sale, the chief accounting officer now directly owns 16,156 shares in the company, valued at approximately $1,454,040. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
BioMarin Pharmaceutical Trading Up 0.8 %
Shares of BMRN stock opened at $92.22 on Friday. The stock has a market cap of $17.40 billion, a price-to-earnings ratio of 104.80, a PEG ratio of 1.72 and a beta of 0.31. The stock has a 50-day moving average of $87.46 and a 200-day moving average of $89.07. The company has a current ratio of 2.51, a quick ratio of 1.57 and a debt-to-equity ratio of 0.12. BioMarin Pharmaceutical Inc. has a 1-year low of $76.02 and a 1-year high of $100.38.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. The company had revenue of $646.21 million during the quarter, compared to analysts' expectations of $639.53 million. BioMarin Pharmaceutical had a return on equity of 5.01% and a net margin of 6.93%. The business's quarterly revenue was up 20.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.11 earnings per share. On average, equities research analysts forecast that BioMarin Pharmaceutical Inc. will post 1.93 earnings per share for the current year.
Institutional Investors Weigh In On BioMarin Pharmaceutical
Protect Your Bank Account Before It’s Too Late
From Weiss Ratings | Ad
For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account.
It gives them the power to monitor every single transaction …
Stop right now and do these 3 things to protect yourself
Several institutional investors and hedge funds have recently made changes to their positions in BMRN. Capital Research Global Investors boosted its position in shares of BioMarin Pharmaceutical by 79.0% during the 4th quarter. Capital Research Global Investors now owns 10,774,641 shares of the biotechnology company's stock valued at $1,038,907,000 after purchasing an additional 4,756,671 shares in the last quarter. Norges Bank bought a new stake in shares of BioMarin Pharmaceutical during the 4th quarter valued at about $324,098,000. Barclays PLC boosted its position in shares of BioMarin Pharmaceutical by 31.6% during the 3rd quarter. Barclays PLC now owns 5,573,157 shares of the biotechnology company's stock valued at $493,111,000 after purchasing an additional 1,336,886 shares in the last quarter. Toronto Dominion Bank boosted its position in shares of BioMarin Pharmaceutical by 1,832.5% during the 3rd quarter. Toronto Dominion Bank now owns 907,754 shares of the biotechnology company's stock valued at $80,318,000 after purchasing an additional 860,782 shares in the last quarter. Finally, Viking Global Investors LP boosted its position in shares of BioMarin Pharmaceutical by 16.0% during the 4th quarter. Viking Global Investors LP now owns 4,889,454 shares of the biotechnology company's stock valued at $471,441,000 after purchasing an additional 673,998 shares in the last quarter. Institutional investors own 98.71% of the company's stock.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the company. Piper Sandler reduced their price target on BioMarin Pharmaceutical from $115.00 to $107.00 and set an "overweight" rating for the company in a research note on Friday, February 23rd. Canaccord Genuity Group restated a "hold" rating and issued a $91.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, February 29th. Stifel Nicolaus reiterated a "buy" rating and set a $101.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, December 21st. Robert W. Baird cut their target price on BioMarin Pharmaceutical from $127.00 to $104.00 and set an "outperform" rating for the company in a research report on Tuesday, January 30th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Seven equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat, BioMarin Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus price target of $107.61.
View Our Latest Report on BMRN
BioMarin Pharmaceutical Company Profile
(
Get Free Report)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
